Clinical Trial Update: Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 clinical trial exploring whether lymphocyte markers can predict response to rituximab in idiopathic nephrotic syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephrotic Syndrome

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: National University Health System, Singapore | Conditions: Nephrotic Syndrome | Phase 3 | Status: UNKNOWN